<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00798447</url>
  </required_header>
  <id_info>
    <org_study_id>HC-G-H-0603</org_study_id>
    <nct_id>NCT00798447</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery</brief_title>
  <official_title>A Prospective, Randomized, Double Blind Study to Compare the Efficacy and Safety of a n-3 Fatty Acid-containing Lipid Emulsion During Parenteral Nutrition in Patients Considered for Major Surgery for Gastric and Colorectal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>B.Braun Taiwan Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the impact of peri- and post-operative parenteral nutrition enriched with n-3
      PUFA on post-operative inflammatory processes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction of pro inflammatory activity</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>GI Cancer</condition>
  <arm_group>
    <arm_group_label>lipid emulsion with n-3 FA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>lipid emulsion without n-3 FA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLF 541</intervention_name>
    <description>22-24 h i.v. infusion, maximum 0.75 ml lipid emulsion per kg BW per hour</description>
    <arm_group_label>lipid emulsion with n-3 FA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipofundin MCT</intervention_name>
    <description>22-24 h iv.infusion, maximum 0.75 ml lipid emulsion per kg BW per hour</description>
    <arm_group_label>lipid emulsion without n-3 FA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients considered for major surgery for gastric and colorectal cancer

          -  expected requirement for post operative PN or TPN of at least 7 days

          -  possibility of PN/TPN provision 1 day prior to surgery

          -  Age &gt;18 years old and &lt;80 years old

          -  Hemodynamically stable

          -  Written Informed consent

        Exclusion Criteria:

          -  Participation in a clinical study with an investigational drug or an investigational
             medical device within one month prior to the start of study

          -  Patients with sepsis, severe sepsis or septic shock

          -  Known or suspected drug abuse

          -  Intrahepatic cholestasis

          -  General contraindications for infusion therapy such as acute pulmonary edema,
             hyperhydration and decompensated cardiac insufficiency

          -  Pregnancy (positive in urine) or lactation

          -  Autoimmune disease e.g. HIV

          -  Known hypersensitivity to egg-, soy-, and fish proteins or any of the ingredients of
             the investigational products

          -  Hemodynamic failure of any origin (hemorrhagic shock, myocardial infarction, cardiac
             failure)

          -  Alterations of coagulation (thrombocytes &lt;150000 /mm3), PT &lt; 50%, PTT &gt; 40 sec

          -  Ketoacidosis caused by Diabetes mellitus within 7 days prior to onset of study

          -  Renal insufficiency with serum creatinine &gt; 1.4 mg/dL (&gt;124 µmol/L)

          -  Patients with severe liver dysfunction with bilirubin &gt;2.5 mg/dL (&gt; 43 µmol/L)

          -  Lipid disorders, in particular fasting serum triglycerides &gt; 250 mg/dL (&gt;2.85 mmol/L),
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital Taipei</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2008</study_first_submitted>
  <study_first_submitted_qc>November 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2008</study_first_posted>
  <last_update_submitted>June 8, 2011</last_update_submitted>
  <last_update_submitted_qc>June 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Manager</name_title>
    <organization>B.Braun Melsungen AG</organization>
  </responsible_party>
  <keyword>post OP</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

